Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug Administration (FDA) in July, the study protocol now…
Thanksgiving is over, but my feeling of gratitude remains. As a single-lung transplant recipient, the holiday is a time for me to contemplate the tremendous gift given to me on Dec. 4, 2015. I have just passed my fourth “lungiversary.” As I look back at my experience, I find it…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A joint research project between BioMed X and Boehringer Ingelheim has identified a new set of potential epigenetic targets for the treatment of two chronic lung diseases, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Epigenetics refers to DNA chemical modifications that can turn genes on or…
Treatment with Esbriet (pirfenidone) before and after cancer removal surgery reduces the risks of acute flares following the procedure in people with idiopathic pulmonary fibrosis (IPF) and lung cancer, a study finds. The findings were reported in “Perioperative pirfenidone treatment for lung cancer patients with…
I love Christmas and all that comes with it: the lights, music, decorations, parades, and Christmas trees. But I know that the season is a stressful and lonely time for some people. Christmas isn’t for everyone. This especially can be true for families facing hardships, or those who are spending…
Idebenone, an antioxidant molecule used to treat Alzheimer’s disease and other brain-damaging conditions, prevented lung damage in a mouse model of pulmonary fibrosis (PF), a study has found. The therapy also improved lung function in mice that had already developed the disease. The study, “…
Algernon Pharmaceuticals has announced its plans to launch its first Phase 2 clinical trial evaluating one of two repurposed compounds — NP-120 for the treatment of idiopathic pulmonary fibrosis (IPF) or NP-178 for inflammatory bowel disease (IBD) — in the second quarter of 2020. This follows…
Patients with idiopathic pulmonary fibrosis (IPF) in Canada face challenges in equal access to quality healthcare services at the national level, with drastic differences between provinces, according to the findings of a new report from the Canadian Pulmonary Fibrosis Foundation (CPFF) and Hoffmann-La Roche. The report, titled…
Healthy eating is a popular topic on the Pulmonary Fibrosis News Forums. Members discuss their attempts to promote optimal pulmonary wellness by improving their eating habits. They also share what foods they avoid because of side effects and what foods help them feel better. Someone once said, “Eat…
Get regular updates to your inbox.
